This grant is for advancing the treatment and management of Neurofibromatosis (NF) through dedicated clinical research. The Department of Defense’s Neurofibromatosis Research Program Clinical Trial Award specifically supports pilot, Phase 0, Phase I, or Phase II clinical trials. The primary objective of this funding is to support research initiatives that hold the potential for a major, transformative impact on the treatment or overall management of Neurofibromatosis. It is crucial to understand that funds from this award mechanism are exclusively designated for clinical trial activities, and cannot be utilized for preclinical research studies. This targeted approach aims to accelerate the translation of scientific discoveries into improved clinical outcomes for individuals affected by NF, fostering innovative therapeutic solutions.
Opportunity ID: 157973
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-12-NFRP-CTA |
| Funding Opportunity Title: | DOD FY12 Neurofibromatosis Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 22, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | May 31, 2012 |
| Current Closing Date for Applications: | May 31, 2012 |
| Archive Date: | Jun 30, 2012 |
| Estimated Total Program Funding: | $2,880,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Neurofibromatosis (NF) Research Program Clinical Trial Award supports pilot and Phase 0, I, or II clinical trials with the potential to have a major impact on the treatment or management of NF. Funding from this award mechansim must support a clinical trial and may not be used for preclinical research studies. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP and eReceipt HELP: 301-682-5507; help@cdmrp.org
Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 157973 Full Announcement-1 -> nfrp_fy12 cta_gg.pdf
Folder 157973 Full Announcement-1 -> fy12 nfrp_cta ind documentation form.pdf
Packages
| Agency Contact Information: | PA HELP and eReceipt HELP: 301-682-5507; help@cdmrp.org Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00110210 | Mar 22, 2012 | May 31, 2012 | View |
Package 1
Mandatory forms
157973 RR_SF424_1_2-1.2.pdf
157973 PerformanceSite_1_4-1.4.pdf
157973 RR_Budget-1.1.pdf
157973 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
157973 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
